Efficacy in patients with advanced disease, overall, and among patients resistant or intolerant to previous treatment with dasatinib or nilotinib or with the BCR-ABL1^T315Imutation. (A-C) AP-CML, (D-F) BP-CML, and (G-I) Ph⁺ ALL. (B-C,E-F,H-I) The 95% confidence intervals are shown. BP-CML includes myeloid BP (n = 52) and lymphoid BP (n = 10). (A) AP-CML: Response at any time. (B) AP-CML: PFS. Progression from AP was defined as death, development of confirmed BP, loss of previous major or minor hematologic response over a 2-week period, or no decrease from baseline levels in percentage of blasts in peripheral blood or bone marrow on all assessments over a 4-week period, or increasing blasts over a 4-week period. (C) AP-CML: OS. (D) BP-CML: Response at any time. (E) BP-CML: PFS. Progression from BP was defined as death, or increasing blasts in peripheral blood or bone marrow over a 4-week period. (F) BP-CML: OS. (G) Ph⁺ ALL: Response at any time. (H) Ph⁺ ALL: PFS. (I) Ph⁺ ALL: OS. NE, not evaluable.